• Profile
Close

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: Mature results from a multicenter, open-label, single-arm, phase 2 study

The Lancet: Gastroenterology & Hepatology Aug 10, 2021

Javle M, Roychowdhury S, Kelley RK, et al. - Infigratinib represents a potential new therapeutic option for previously treated patients with locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements, as it showed promising clinical activity and a manageable adverse event profile in this setting.

  • In this multicenter, open-label, single-arm, phase 2 study, patients were administered 125 mg of oral infigratinib once daily for 21 days of 28-day cycles until disease progression, intolerance, withdrawal of consent, or death.

  • The blinded independent central review-assessed objective response rate of 23·1% was recorded after a median follow-up of 10·6 months, with one confirmed complete response in a patient who only had non-target lesions identified at baseline and 24 partial responses.

  • Hyperphosphatemia, stomatitis, fatigue, and alopecia were the most common treatment-emergent adverse events.

  • Dry eyes were the most common ocular toxicity observed.

  • No treatment-related deaths were recorded.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay